This acquisition aims to further strengthen the position of VIANEX in the generics market, since PHARMANEL S.A. possesses a significant portfolio and expertise in this field. This investment constitutes proof of the principles governing the operation of VIANEX, aiming to continuously expand and upgrade the services provided by the company, always focusing on the doctrine of the company’s founder, Pavlos Giannakopoulos, ‘Quality in Production - Caring for People’.

Commenting on the acquisition, the Chairman and Chief Executive Officer of VIANEX Group, Dimitris P. Giannakopoulos, stated:

«VIANEX continues to invest in the field of pharmaceuticals, despite adverse market conditions and the disadvantageous framework shaped by the government over many years. This acquisition proves that our goal is to further strengthen Greek pharmaceuticals, by implementing a contemporary and dynamic business model, which is always focused on quality and reliability».

On behalf of PHARMANEL S.A., the retiring President and Managing Director of the company, Ms Violetta Mavrommati, noted:

«This move ensures the company's viability and jobs and marks the beginning of a new growth path».